David Jones Sells 1,028 Shares of Innospec (NASDAQ:IOSP) Stock

Innospec Inc. (NASDAQ:IOSP) SVP David Jones sold 1,028 shares of Innospec stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $75.64, for a total transaction of $77,757.92. Following the transaction, the senior vice president owned 14,693 shares of the company’s stock, valued at $1,111,378.52. This represents a 6.54% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Innospec Stock Performance

IOSP stock opened at $77.02 on Thursday. The business has a 50-day simple moving average of $81.05 and a two-hundred day simple moving average of $79.07. The company has a market capitalization of $1.91 billion, a P/E ratio of 16.46, a price-to-earnings-growth ratio of 2.01 and a beta of 0.90. Innospec Inc. has a 52-week low of $70.10 and a 52-week high of $102.25.

Innospec (NASDAQ:IOSP) last issued its quarterly earnings data on Tuesday, February 17th. The specialty chemicals company reported $1.50 EPS for the quarter, topping the consensus estimate of $1.26 by $0.24. Innospec had a return on equity of 10.18% and a net margin of 6.56%.The firm had revenue of $455.60 million during the quarter, compared to the consensus estimate of $460.87 million. During the same period in the prior year, the business posted $1.41 earnings per share. The company’s quarterly revenue was down 2.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Innospec Inc. will post 6.18 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Innospec

A number of hedge funds and other institutional investors have recently made changes to their positions in IOSP. Caitong International Asset Management Co. Ltd grew its position in Innospec by 316.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 662 shares of the specialty chemicals company’s stock valued at $51,000 after buying an additional 503 shares during the period. Invesco Ltd. grew its position in shares of Innospec by 29.4% during the 4th quarter. Invesco Ltd. now owns 104,639 shares of the specialty chemicals company’s stock valued at $8,009,000 after acquiring an additional 23,794 shares during the period. Mercer Global Advisors Inc. ADV grew its position in shares of Innospec by 19.4% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 7,535 shares of the specialty chemicals company’s stock valued at $577,000 after acquiring an additional 1,226 shares during the period. Vident Advisory LLC purchased a new stake in shares of Innospec during the 4th quarter worth approximately $651,000. Finally, NewEdge Advisors LLC raised its holdings in shares of Innospec by 21.4% in the 4th quarter. NewEdge Advisors LLC now owns 6,511 shares of the specialty chemicals company’s stock worth $498,000 after purchasing an additional 1,148 shares during the period. 96.64% of the stock is owned by hedge funds and other institutional investors.

Key Innospec News

Here are the key news stories impacting Innospec this week:

• Positive Sentiment: Large institutional accumulation reported — Western Standard, Goldman Sachs, Millennium Management and Norges Bank all increased or initiated positions, signalling heavy institutional demand that can support the share price. Institutional Ownership and Activity
• Neutral Sentiment: Short-interest update published; this doesn’t change fundamentals but could amplify moves if short positions cover or build. Short Interest Update
• Neutral Sentiment: Analyst coverage is mixed — upgrades from some boutique services offset by a Zacks downgrade; MarketBeat shows a consensus tilt toward “Reduce,” which may limit upside until guidance or fundamentals improve. Analyst Ratings
• Negative Sentiment: SVP David B. Jones sold 1,028 shares at an average $75.64 (~$77.8k); his stake declined ~6.5% — insider selling can be perceived negatively by the market. David B. Jones Sale
• Negative Sentiment: Director David Landless sold 594 shares at $76.56 (~$45.5k); his holding dropped ~7.2%. David Landless SEC Filing
• Negative Sentiment: Director Larry Padfield sold 594 shares at $76.56 (~$45.5k); his stake declined ~5.9%. Larry Padfield Sale
• Negative Sentiment: Director Milton C. Blackmore sold 594 shares at $76.56 (~$45.5k); position down ~5.3%. Milton C. Blackmore Sale
• Negative Sentiment: Director Claudia Poccia sold 119 shares at $76.56 (~$9.1k); a smaller, but additional insider sale disclosed via SEC filing. Claudia Poccia SEC Filing

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Zacks Research downgraded shares of Innospec from a “hold” rating to a “strong sell” rating in a report on Thursday, February 19th. Wall Street Zen upgraded shares of Innospec from a “hold” rating to a “buy” rating in a report on Saturday, December 13th. Finally, Weiss Ratings raised shares of Innospec from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, February 19th. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Innospec currently has a consensus rating of “Reduce”.

Innospec Company Profile

Innospec Incorporated (NASDAQ: IOSP) is a global specialty chemicals company headquartered in Cleveland, Ohio. The company operates through three principal business segments: Fuel Specialties, Oilfield Services, and Performance Chemicals. In the Fuel Specialties segment, Innospec develops and supplies additives designed to enhance octane levels, improve combustion efficiency, reduce emissions and prevent deposit formation in gasoline and diesel engines. Its Oilfield Services division provides chemical technologies—such as surfactants, corrosion inhibitors and demulsifiers—to support exploration, drilling, production optimization and enhanced oil recovery operations.